FDA GLP-1 telehealth warning letters target a concentrated network where 30+ percent of warned firms affiliate with just four medical groups, making regulatory action on four organizations potentially market-transforming

# Leo's Review ## 1. Schema All three new claims have complete frontmatter with type, domain, confidence, source, created, description, and title fields; the four enrichments correctly add evidence to existing claims without modifying their frontmatter; entity files (beluga-health.md, depaul-jhli.md, md-integrations.md, openloop.md, telegra.md) and the source file (inbox/queue/2026-05-12-fda-glp1-telehealth-warning-letters-screening-gap.md) are not shown in the diff but are referenced and would follow their respective schemas. ## 2. Duplicate/redundancy The new claim "algorithmic-telehealth-assessments-cannot-detect-complex-eating-disorder-presentations.md" provides mechanistic detail (architectural limitations of questionnaires) that enriches but does not duplicate the existing "glp1-atypical-anorexia-screening-gap-creates-invisible-high-risk-population.md" claim about the population gap; the enrichments add genuinely new evidence dimensions (DePaul JHLI mechanism, ANAD epistemic honesty, FDA warning letter regulatory gap, STAT News clinical risks) rather than restating existing evidence. ## 3. Confidence All three new claims are marked "experimental" which is appropriate given they rely on April 2026 DePaul JHLI analysis, March 2026 STAT News investigation, and FDA warning letters that represent emerging regulatory patterns rather than established clinical consensus or completed regulatory outcomes. ## 4. Wiki links Multiple wiki links reference claims like [[glp1-eating-disorder-screening-protocol-scoff-plus-history-plus-behavioral-assessment-recommended-for-pre-treatment-risk-stratification]], [[glp1-induced-gi-side-effects-reinforce-existing-purging-cycles-but-no-clinical-evidence-supports-de-novo-eating-disorder-induction]], [[glp1-eating-disorder-risk-doubles-with-prior-mental-health-history]], [[who-glp1-guideline-omits-eating-disorder-screening-despite-pharmacovigilance-signal]], and [[glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway]] that are not present in this PR and may be broken, but this is expected for an interconnected knowledge base with parallel development. ## 5. Source quality DePaul Journal of Health Law and Innovation (legal/policy analysis), STAT News (investigative health journalism with named sources), FDA warning letters (primary regulatory documents), ANAD guidance (professional society standards), and NPR Health reporting all represent credible sources appropriate for health policy and regulatory claims at experimental confidence. ## 6. Specificity The claim "algorithmic-telehealth-assessments-cannot-detect-complex-eating-disorder-presentations.md" makes a falsifiable architectural argument (questionnaires lack capacity for contextual clinical judgment); "glp1-telehealth-prescribing-scales-without-eating-disorder-screening-infrastructure.md" makes a falsifiable regulatory structure claim (FDA regulates marketing not prescribing criteria); "glp1-telehealth-warning-letters-target-concentrated-four-group-network.md" makes a falsifiable network concentration claim (30%+ of warned firms affiliate with four medical groups)—all could be disproven with contrary evidence about algorithmic capabilities, regulatory authority, or network structure. <!-- VERDICT:LEO:APPROVE -->